A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with docetaxel to placebo in combination with docetaxel in first line metastatic Castrate Resistant Prostate Cancer (mCRPC)
Phase of Trial: Phase III
Latest Information Update: 05 Mar 2018
At a glance
- Drugs Masitinib (Primary) ; Docetaxel
- Indications Prostate cancer
- Focus Registrational; Therapeutic Use
- Sponsors AB Science
- 28 Dec 2017 Planned number of patients changed from 581 to 580.
- 24 Feb 2014 New trial record
- 20 Feb 2014 This trial has been authorised by competent authorities and has been initiated according to an AB Science media release.